Advertisement
Letter to the Editor| Volume 99, P116-117, May 2022

Appropriate dosing of the individual direct oral anticoagulants in atrial fibrillation: Differences in the questions to be answered

Published:January 07, 2022DOI:https://doi.org/10.1016/j.ejim.2022.01.014
Appropriate dosing of the individual direct oral anticoagulants in atrial fibrillation: Differences in the questions to be answered
Previous ArticleOne-year mepolizumab for Allergic bronchopulmonary aspergillosis: Focus on steroid sparing effect and markers of response
Next ArticleSecondary hyperaldosteronism and liver fibrosis in patients with compensated chronic liver disease or portal hypertension

      Keywords

      Direct oral anticoagulants; Apixaban; Dabigatran; Edoxaban; Rivaroxaban
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Steffel J.
        • Collins R.
        • Antz M.
        • Cornu P.
        • Desteghe L.
        • Haeusler K.G.
        • et al.
        2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.
        Europace. 2021; 23: 1612-1676https://doi.org/10.1093/europace/euab065
        View in Article
        • Rubboli A.
        Horizontal vs. vertical dose reduction of direct oral anticoagulants in patients with non-valvular atrial fibrillation: definition and implications for practice.
        Eur J Intern Med. 2019; 62: e11-e12https://doi.org/10.1016/j.ejim.2019.01.005
        View in Article

      3. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000829/human_med_000981.jsp.

        View in Article
        • Steinberg B.A.
        • Shrader P.
        • Thomas L.
        • Ansell J.
        • Fonarow G.C.
        • Gersh B.J.
        • et al.
        ORBIT-AF investigators and patients. Off-label dosing of non-vitamin K antagonist oral anticoagulants and adverse outcomes: the ORBIT-AF II registry.
        J Am Coll Cardiol. 2016; 68: 2597-2604https://doi.org/10.1016/j.jacc.2016.09.966
        View in Article
        • Camm A.J.
        • Cools F.
        • Virdone S.
        • Bassand J.P.
        • Fitzmaurice D.A.
        • Fox K.A.A.
        • et al.
        GARFIELD-AF investigators. Mortality in patients with atrial fibrillation receiving nonrecommended doses of direct oral anticoagulants.
        J Am Coll Cardiol. 2020; 76: 1425-1436https://doi.org/10.1016/j.jacc.2020.07.045
        View in Article

      Article info

      Publication history

      Published online: January 07, 2022
      Accepted: January 3, 2022
      Received: December 29, 2021

      Identification

      DOI: https://doi.org/10.1016/j.ejim.2022.01.014

      Copyright

      © 2022 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect
      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


      RELX